Merck & Co Inc: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Merck & Co Inc Unternehmen

Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.

Merck & Co Inc Informationen



BörsenkürzelMRK

Name des UnternehmensMerck & Co Inc

IPO-datumFeb 06, 2077

CEODavis (Robert M)

Anzahl der mitarbeiter75000

WertpapierartOrdinary Share

GeschäftsjahresendeFeb 06

Addresse126 East Lincoln Avenue

StadtRAHWAY

BörseNASDAQ OMX NASDAQ Basic NYSE

LandUnited States of America

Postleitzahl07065

Telefon19087404000

Websitehttps://www.merck.com/

BörsenkürzelMRK

IPO-datumFeb 06, 2077

CEODavis (Robert M)

Führungskräfte von Merck & Co Inc



Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Robert M. (Rob) Davis

Chairman of the Board, President, Chief Executive Officer

450.35K

+1.50%

Mr. Sanat Chattopadhyay

Executive Vice President and President - Merck Manufacturing Division

200.68K

+0.73%

Dr. Dean Y. Li, M.D., Ph.D.

Executive Vice President, President - Merck Research Laboratories

94.43K

+2.54%

Ms. Jennifer L. Zachary

Executive Vice President, General Counsel

70.41K

+2.13%

Mr. Chirfi Guindo

Senior Vice President, Chief Marketing Officer - Human Health

56.20K

+1.78%

Mr. Joseph Edward Romanelli

Senior Vice President, President - MSD International Human Health

28.61K

+19.93%

Ms. Patricia F. Russo

Independent Director

13.15K

--

Mr. Thomas Henry (Tom) Glocer, J.D.

Lead Independent Director

5.10K

--

Mr. Inge G. Thulin

Independent Director

2.93K

--

Ms. Pamela J. Craig

Independent Director

1.72K

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Robert M. (Rob) Davis

Chairman of the Board, President, Chief Executive Officer

450.35K

+1.50%

Mr. Sanat Chattopadhyay

Executive Vice President and President - Merck Manufacturing Division

200.68K

+0.73%

Dr. Dean Y. Li, M.D., Ph.D.

Executive Vice President, President - Merck Research Laboratories

94.43K

+2.54%

Ms. Jennifer L. Zachary

Executive Vice President, General Counsel

70.41K

+2.13%

Mr. Chirfi Guindo

Senior Vice President, Chief Marketing Officer - Human Health

56.20K

+1.78%

Mr. Joseph Edward Romanelli

Senior Vice President, President - MSD International Human Health

28.61K

+19.93%

Umsatzaufteilung

Währung: USDAktualisiert: Mon, Apr 6

FY2025

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Oncology-Keytruda

31.64B

48.67%

Vaccines -Gardasil/Gardasil

5.23B

8.05%

Animal Health-Livestock

3.90B

5.99%

Other pharmaceutical

2.92B

4.49%

Animal Health-Companion Animals

2.46B

3.78%

Andere

18.86B

29.02%

Nach RegionUSD

Name

Umsatz

Anteil

United States

36.51B

56.16%

Europe, Middle East and Africa

14.58B

22.43%

Latin America

3.41B

5.25%

Asia Pacific (Other than China and Japan)

2.98B

4.59%

Other

2.88B

4.43%

Andere

4.65B

7.15%

Nach Geschäftsbereich

Nach Region

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Oncology-Keytruda

31.64B

48.67%

Vaccines -Gardasil/Gardasil

5.23B

8.05%

Animal Health-Livestock

3.90B

5.99%

Other pharmaceutical

2.92B

4.49%

Animal Health-Companion Animals

2.46B

3.78%

Andere

18.86B

29.02%

Aktionärsstatistik

Aktualisiert: Sun, May 10

Aktionäre

Aktionärstypen

Aktionäre

Anteil

Vanguard Capital Management, LLC

6.52%

BlackRock Institutional Trust Company, N.A.

5.51%

State Street Investment Management (US)

4.86%

Wellington Management Company, LLP

3.50%

Vanguard Portfolio Management, LLC

2.73%

Andere

76.88%

Aktionäre

Anteil

Vanguard Capital Management, LLC

6.52%

BlackRock Institutional Trust Company, N.A.

5.51%

State Street Investment Management (US)

4.86%

Wellington Management Company, LLP

3.50%

Vanguard Portfolio Management, LLC

2.73%

Andere

76.88%

Aktionärstypen

Aktionäre

Anteil

Investment Advisor

42.43%

Investment Advisor/Hedge Fund

27.18%

Research Firm

3.05%

Pension Fund

2.68%

Bank and Trust

2.21%

Sovereign Wealth Fund

1.63%

Hedge Fund

1.38%

Insurance Company

0.70%

Family Office

0.12%

Andere

18.61%

Institutionelle Beteiligung



Aktualisiert: Sun, Apr 5

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2026Q1

5687

2.01B

81.41%

-10.60M

2025Q4

5433

1.99B

80.26%

-56.89M

2025Q3

5358

2.02B

81.35%

-45.75M

2025Q2

5398

2.02B

80.82%

-16.42M

2025Q1

5446

2.05B

81.47%

-3.32M

2024Q4

5410

2.04B

80.88%

+11.87M

2024Q3

5200

2.01B

79.47%

-7.96M

2024Q2

5181

2.01B

79.28%

-4.86M

2024Q1

5154

2.00B

78.88%

-6.10M

2023Q4

5065

1.99B

78.60%

+584.81K

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

BlackRock Institutional Trust Company, N.A.

136.21M

5.51%

-4.94M

-3.50%

Dec 31, 2025

State Street Investment Management (US)

120.04M

4.86%

+1.86M

+1.57%

Dec 31, 2025

Wellington Management Company, LLP

86.44M

3.5%

+11.16M

+14.82%

Dec 31, 2025

Geode Capital Management, L.L.C.

60.05M

2.43%

+249.11K

+0.42%

Dec 31, 2025

Charles Schwab Investment Management, Inc.

48.56M

1.96%

-5.14M

-9.56%

Dec 31, 2025

Norges Bank Investment Management (NBIM)

37.98M

1.54%

+1.87M

+5.18%

Dec 31, 2025

Fidelity Management & Research Company LLC

33.75M

1.36%

+6.13M

+22.20%

Dec 31, 2025

Fisher Investments

24.87M

1.01%

+805.20K

+3.35%

Dec 31, 2025

Verbundene ETFs



Aktualisiert: Sat, Dec 6

Name

Anteil

VanEck Pharmaceutical ETF

16.09%

FT Vest DJIA Dogs 10 Target Income ETF

10.79%

First Trust NASDAQ Pharmaceuticals ETF

7.94%

Invesco Dow Jones Industrial Average Dividend ETF

6.94%

First Trust Morningstar Dividend Leaders Index Fund

5.39%

Coastal Compass 100 ETF

5.13%

Invesco Pharmaceuticals ETF

4.96%

VanEck Morningstar Wide Moat Value ETF

4.73%

Vaneck Durable High Dividend ETF

4.65%

Franklin Income Focus ETF

4.56%

VanEck Pharmaceutical ETF

Anteil16.09%

FT Vest DJIA Dogs 10 Target Income ETF

Anteil10.79%

First Trust NASDAQ Pharmaceuticals ETF

Anteil7.94%

Invesco Dow Jones Industrial Average Dividend ETF

Anteil6.94%

First Trust Morningstar Dividend Leaders Index Fund

Anteil5.39%

Coastal Compass 100 ETF

Anteil5.13%

Invesco Pharmaceuticals ETF

Anteil4.96%

VanEck Morningstar Wide Moat Value ETF

Anteil4.73%

Vaneck Durable High Dividend ETF

Anteil4.65%

Franklin Income Focus ETF

Anteil4.56%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 28.91B USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Jan 27, 2026

MRK.NB Interim Cash Dividend of gross USD 0.85 paid on Apr 07, 2026 going ex on Mar 16, 2026

Mar 16, 2026

Apr 07, 2026

Mar 16, 2026

Nov 18, 2025

MRK.NB Interim Cash Dividend of gross USD 0.85 paid on Jan 08, 2026 going ex on Dec 15, 2025

Dec 15, 2025

Jan 08, 2026

Dec 15, 2025

Jul 22, 2025

MRK.NB Final Cash Dividend of gross USD 0.81 paid on Oct 07, 2025 going ex on Sep 15, 2025

Sep 15, 2025

Oct 07, 2025

Sep 15, 2025

May 27, 2025

MRK.NB Interim Cash Dividend of gross USD 0.81 paid on Jul 08, 2025 going ex on Jun 16, 2025

Jun 16, 2025

Jul 08, 2025

Jun 16, 2025

Jan 28, 2025

MRK.NB Interim Cash Dividend of gross USD 0.81 paid on Apr 07, 2025 going ex on Mar 17, 2025

Mar 17, 2025

Apr 07, 2025

Mar 17, 2025

Nov 19, 2024

MRK.NB Final Cash Dividend of gross USD 0.81 paid on Jan 08, 2025 going ex on Dec 16, 2024

Dec 16, 2024

Jan 08, 2025

Dec 16, 2024

Jul 23, 2024

MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Oct 07, 2024 going ex on Sep 16, 2024

Sep 16, 2024

Oct 07, 2024

Sep 16, 2024

May 29, 2024

MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Jul 08, 2024 going ex on Jun 17, 2024

Jun 17, 2024

Jul 08, 2024

Jun 17, 2024

Jan 23, 2024

MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Apr 05, 2024 going ex on Mar 14, 2024

Mar 15, 2024

Apr 05, 2024

Mar 14, 2024

Nov 28, 2023

MRK.NB Final Cash Dividend of gross USD 0.77 paid on Jan 08, 2024 going ex on Dec 14, 2023

Dec 15, 2023

Jan 08, 2024

Dec 14, 2023

Aktien-Split



Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten

Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten